Press Releases

Stay Updated

Press Releases

STATEMENT: Patients Score Fifth Legal Victory As Court Rejects Boehringer Ingelheim Challenge To Medicare Negotiation Program

Federal Judge Upholds Medicare’s Drug Price Negotiation Program, Ruling For Patients And Rejecting Pharmaceutical Industry Lawsuit WASHINGTON D.C. — Dealing another major blow to Big Pharma’s coordinated legal assault on Medicare negotiation, on Wednesday, July 3rd, a federal judge in Connecticut ruled against Boehringer Ingelheim’s legal challenge to Medicare’s authority to negotiate lower drug prices. […]

Press Releases

STATEMENT: Patients For Affordable Drugs’ Responds To Boehringer Ingelheim’s Oral Arguments In Corporation’s Lawsuit Against Medicare Negotiation

Patients For Affordable Drugs Continues to Fight Against Big Pharma’s Attempts to Undermine Medicare Drug Price Negotiation WASHINGTON, D.C. — Oral arguments were presented today in the case brought by Boehringer Ingelheim Pharmaceuticals challenging Medicare’s authority to negotiate lower drug prices for patients. During the proceedings, the judge expressed skepticism about the harm the pharmaceutical […]

Press Releases

STATEMENT: AstraZeneca Files Notice To Appeal Judge’s Ruling, Doubling Down On Effort To Block Medicare Negotiation

Patients For Affordable Drugs Responds to AstraZeneca’s Plan to Challenge March 1, 2024 Decision on Its Lawsuit to Stop Medicare Negotiation Program WASHINGTON D.C. — The ongoing legal assault on Medicare negotiation continues as AstraZeneca has filed a notice to appeal a federal judge’s ruling against the company’s lawsuit to overturn the program. AstraZeneca’s blockbuster drug, […]

Press Releases

STATEMENT: Patients Claim Victory As Fourth Judge Rejects Drug Companies’ Lawsuits To Block Medicare Negotiation

Federal Court Rejects Big Pharma’s “Strongest Arguments” Challenging Constitutionality of Medicare Negotiation Program, Marking Another Win For Patients WASHINGTON, D.C. — Dealing a major blow to Big Pharma’s efforts to block Medicare from negotiating drug prices, a federal district court in New Jersey has ruled against constitutional challenges brought by pharmaceutical giants Bristol Myers Squibb […]

Press Releases

Patients For Affordable Drugs Launches New Website Aimed At Defending Medicare Negotiation

Patients For Affordable Drugs has launched our new campaign tool: FightPharma.org. This website will serve as a dedicated platform for our ongoing campaign US vs. Pharma; Fighting to Protect Medicare Negotiation, aimed at leveraging patient stories, including via Amicus Briefs, to counter Big Pharma’s legal efforts to stop the implementation of Medicare negotiation. By amplifying […]

Press Releases

STATEMENT: Patients For Affordable Drugs’ Statement On Oral Arguments In Four Lawsuits Against Medicare Drug Price Negotiation

Patients For Affordable Drugs Continues to Fight Against Big Pharma’s Attempts to Undermine Medicare Drug Price Negotiation As Some Of The Largest Drug Companies Have Their Day In Court   WASHINGTON, D.C. —  Oral arguments were presented today in four cases brought by Bristol Myers Squibb (BMS), Johnson & Johnson (J&J), Novartis, and Novo Nordisk […]

Press Releases

STATEMENT: Judge Rejects Another Drug Company Lawsuit Aimed At Blocking Medicare Negotiation

Patients For Affordable Drugs Responds to Judge’s Ruling Against AstraZeneca in The Pharmaceutical Corporation’s Lawsuit Against Medicare Drug Price Negotiation   WASHINGTON, D.C. — Today marked a significant moment in the ongoing fight to lower prescription drug prices as a federal judge in Delaware issued a sweeping ruling against AstraZeneca in a case brought by […]

Press Releases

Patients For Affordable Drugs Statement On Oral Arguments In AstraZeneca Lawsuit Against Medicare Drug Price Negotiation

Patients For Affordable Drugs Continues Fight Against Big Pharma’s Attempts To Undermine Medicare Drug Price Negotiation In Landmark Case: AstraZeneca Pharmaceuticals LP et al. v. Becerra et al.   WASHINGTON, D.C. — Today marked an important moment in the battle for affordable prescription drugs as oral arguments were presented in the case of AstraZeneca Pharmaceuticals LP […]